Prospective cohort involving repeated medical PET-CT imaging with a new radiotracer (FAPI)
Key facts
- Where
- Saint-Cloud, FranciaországSee the site
- Phase
- 1/2. fázis
Where in Franciaország
- Institut CurieSaint-Cloud, FranciaországTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Institut Curie
- Trial code
- EU 2024-512467-31-00
- Record updated
- 2026. szeptember 28.
- Original description
To design imaging biomarkers from 68Ga-FAPI PET/CT images at baseline and assess their association with patient’s prognosis.Read full original descriptionShow less
"INDIGO-FAPI": Cutting Edge Imaging for Earlier Pancreatic Cancer Diagnosis: evaluation of Positron Emission Tomography (PET) with the Fibroblast Activation Protein Inhibitor (FAPI)
To design imaging biomarkers from 68Ga-FAPI PET/CT images at baseline and assess their association with patient’s prognosis.
Inclusion: Cyto/histologically proven PDAC; Non-metastatic proven PDAC on recent (< 1 month) CT-scan and MRI; Concomitant enrollment in the HoMING prospective cohort (Sponsor: AP-HP, NCT04363983); Age > 18 years old; Affiliation to a social security scheme; Signed informed consent.
Exclusion: Protected adults (guardianship, curatorship or safeguarding justice); Pregnant or breastfeeding woman; Women of childbearing potential not using one highly effective method of contraception during the screening period, during the course of the study and at least 4 months after the last administration of study treatment (see added appendix 4).